Real-world study of Envarsus in kidney transplant with AI
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how well a once-daily extended-release tacrolimus (Envarsus) works in real-life for kidney transplant patients. It uses artificial intelligence to help understand treatment patterns and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You received a kidney transplant from a living or deceased donor.
- You started taking Envarsus (a once-daily extended-release tacrolimus) within 24 hours after transplant.
- You are willing to take part and do not object to your health data being used.
- You are covered by a social security scheme.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This study looks at whether Envarsus XR helps prevent “subclinical” (not obviously noticeable) kidney transplant rejection by changing blood immune test results. You may be able to join if you recently received a kidney transplant and can take the study medicine as required.
This trial looks at whether changing your maintenance anti-rejection medicine from Prograf (usually twice daily) to Envarsus (once daily) can help keep your liver and kidney function stable. It targets people who may be having kidney side effects, symptoms from tacrolimus, or trouble taking a twice-daily medicine.
This trial studies whether taking an extended-release form of tacrolimus (a medicine to prevent transplant rejection) after a liver transplant works well for people who are followed at the University of Alberta. It may help simplify dosing and monitor safety and effectiveness after transplant.
This study compares two long-acting forms of tacrolimus (Envarsus and Advagraf) to see how the body processes them after a kidney transplant. It aims to find the best way to use these medications to prevent organ rejection.
Hear when a new Chronic Renal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.